FLT3 and acute myeloid leukemia: Anti-FLT3 CAR T-cell therapy can be genetically engineered to harbor an off switch to deplete the therapy before transplantation or after the AML has been eliminated and normal immune reconstitution from FLT3-proficient HSPCs can occur.